New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare...
Approved a little more than a year ago by the U.S. Food and Drug Administration, palopegteriparatide was lauded by a panel of experts from around the world in a recently published consensus statement on hypoparathyroidism treatment. Aliya Khan, MD, talks to Endocrine News what this means for these patients’ treatment options, quality of life, and...
The JCEM Case Reports Clinical Pearls session at ENDO 2025 featured three presentations of rare challenging endocrine cases that could answer questions for endocrinologists who could be treating patients with similar symptoms, possibly triggering further investigations that might lead to optimal outcomes. The audience for the third-annual JCEM Case Reports Clinical Pearls session at ENDO...
A new study in The Journal of Clinical Endocrinology & Metabolism has revealed a concerning paradox in the management of osteoporosis in the United States. While the use of drug therapies for the bone-weakening disease has increased over the last decade, a significant and persistent trend of underdiagnosis means millions of high-risk patients are missing...
Divya Sistla, MD, FACP, a steering committee member of the Endocrine Society’s Early-Career Special Interest Group (SIG), discusses how the University of Pittsburgh Medical Center uses a multidisciplinary approach to successfully improve osteoporosis treatment via a fracture liaison service. In the United States, approximately 2 million new cases of osteoporotic fractures are diagnosed annually. This...
People who skip breakfast and eat late dinners may have an increased risk of developing osteoporosis, according to a new study published in the Journal of the Endocrine Society. Lifestyle habits, such as exercise, alcohol consumption and smoking, are known to increase people’s risk of osteoporosis, however little is known about the association between osteoporotic fracture...
Each May in the U.S. is National Osteoporosis Awareness and Prevention Month which is observed to raise awareness about osteoporosis, promote prevention, and early detection. Bone health is one of the cornerstones of endocrine science and practice, so we felt that this was the perfect issue to take a look at some of the recent...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare...
Each May in the U.S. is National Osteoporosis Awareness and Prevention Month which is observed to raise awareness about osteoporosis, promote prevention, and early detection. Bone health is one of the cornerstones of endocrine science and practice, so we felt that this was the perfect issue to take a look at some of the recent...
